Patients with major residua had increased risks for postdischarge mortality, transplant, late reintervention<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, June 21, 2022 (HealthDay News) — Among transplant-free survivors requiring predischarge reinterventions after congenital cardiac surgery, those with persistent major residua have significantly worse long-term outcomes, according to a study published in the June 28 issue of the Journal of the American College of Cardiology<\/em>.<\/p>\n Aditya Sengupta, M.D., from Boston Children’s Hospital, and colleagues assessed the long-term outcomes of transplant-free survivors of hospital discharge requiring predischarge reinterventions after surgery for congenital heart disease. The analysis included 408 patients treated from 2011 through 2019.<\/p>\n The researchers reported 58 postdischarge deaths or transplants (14.2 percent) and 208 late reinterventions (51.0 percent) at a median follow-up of 3.0 years. Worse transplant-free survival and freedom from reintervention were seen with greater predischarge residual lesion severity. Compared with grade 1 patients (no residua), grade 3 patients (major residua) had an increased risk for postdischarge mortality or transplant (hazard ratio, 4.8) and late reintervention (subdistribution hazard ratio, 2.1).<\/p>\n “Understanding the factors responsible for residual anatomic defects after surgery for congenital heart disease, particularly those involving the atrioventricular valves, could improve patient selection for individualized corrective strategies,” the authors write.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n